Navigation Links
Mylan Wins Generic Prilosec(R) Patent Litigation
Date:6/10/2008

Court of Appeals Affirms No Infringement

PITTSBURGH, June 10 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a May 2007 District Court ruling stating that Mylan's 10 mg and 20 mg Omeprazole delayed-release capsules do not infringe patents asserted against Mylan by AstraZeneca. Omeprazole is the generic version of AstraZeneca LP's Prilosec(R).

Mylan launched its Omeprazole products on August 4, 2003, despite the patent infringement litigation, which at the time was unprecedented in the generic pharmaceutical industry.

"Once again, we are pleased to have prevailed in court, and we believe that this decision ends the patent litigation surrounding this product for our company," said Mylan Vice Chairman and CEO Robert J. Coury. "Our original decision to launch this product means that consumers, the government and third-party payors have benefited significantly for nearly five years because they've had access to a lower-cost generic version of Prilosec."

Mylan Inc., with a presence in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R)
2. Mylan Announces Final FDA Approval for Zaleplon Capsules
3. Mylan Inc. Acquires Central Eastern European Generics Businesses of Merck KGaA
4. Mylan Launches Paroxetine Hydrochloride Extended-Release Tablets
5. Mylan Schedules Financial Results Conference Call and Live Webcast for the First Quarter Fiscal 2008
6. Mylan Declares Quarterly Preferred Stock Dividend
7. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
8. Mylan Announces Final FDA Approval for Trandolapril Tablets
9. Mylan Announces Final FDA Approval for Felodipine Extended-Release Tablets, USP
10. Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter
11. Mylan Announces Appointment of Jagdish Dore as CEO and Managing Director of Matrix Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... ... today announced the official relaunch of its community and education hub for women ... Eggsurance's mission is to create a safe and welcoming place for women to ...
(Date:5/24/2016)... ... May 24, 2016 , ... The Radiosurgery Society (RSS), ... radiosurgery, is recognizing five medical residents and students for their outstanding contributions to ... The awards will be presented at the 2016 SRS/SBRT Scientific Meeting taking place ...
(Date:5/24/2016)... ... May 24, 2016 , ... The number of health ... or 10% over last year, according to data in the forthcoming AIS’s Directory ... comparatively stable, with a slight decrease in risk-based groups and a slight increase ...
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic Aqua® Research Water ... years and a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss healthier ... May 16, 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated to ...
(Date:5/24/2016)... ... ... WaterAid launched the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 ... world who do not have access to a toilet, even when they’re on their periods. ... #perioddrama. The (sometimes hilarious) results help shine a light on the awkwardness that women face ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... SAN FRANCISCO , May 23, 2016 ... expected to reach USD 5.0 billion by 2022, according ... The increasing generation of medical waste coupled with the ... healthcare industry is expected to drive the demand for ... with these devices as compared to that of the ...
(Date:5/20/2016)... 2016 The Biotech arena remains ... the industry is not far from recovering. There are ... the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ... ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... Sign up for your free trading alerts on these ...
(Date:5/19/2016)... Calif. , May 19, 2016  According ... thirds of the world lacks basic diagnostic imaging. ... in the United States , ... to such technology. In fact, the WHO reports ... risk of avoidable or treatable death, simply due ...
Breaking Medicine Technology: